GenScript Biotech Corporation (HKG: 1548), a leading Contract Research Organization (CRO) based in China, has announced that its subsidiary, Legend Biotech Corporation (NASDAQ: LEGN), achieved sales of USD 157 million for its BCMA-directed chimeric antigen receptor T cell (CAR-T) therapy, Carvykti (ciltacabtagene autoleucel), in the first quarter of 2024, which ended on March 31, 2024.
Carvykti is being commercialized globally by Janssen Biotech, a subsidiary of Johnson & Johnson, in the US, Europe, and other markets. The therapy received its first major market approvals in 2023, beginning with the US in March, followed by the European Medicines Agency (EMA) in May, and later in Japan. It is indicated for heavily pre-treated patients with relapsed/refractory multiple myeloma (MM). The drug is currently awaiting its first regulatory decision in China and has generated a total of USD 500 million in sales for the year 2023. – Flcube.com
